Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several clinical-trial and bleeding-related statements align with the provided label excerpts, but multiple claims are unsupported or conflict with on-label information (e.g., “often used” and “relatively low” bleeding risk; patent-expiration claim). Omitted key dosing/admin details further limit adherence.
Category Scores
Accurate Statements
Vascepa (icosapent ethyl) is a prescription medication.
The provided label excerpts do not explicitly state “prescription medication,” but the label is for VASCEPA and includes professional prescribing sections (1 INDICATIONS AND USAGE, 2 DOSAGE AND ADMINISTRATION).
Vascepa is approved to reduce risk of cardiovascular events in patients with high triglycerides.
1 INDICATIONS AND USAGE: adjunct to maximally tolerated statin therapy in adult patients with elevated triglyceride (TG) levels and established CVD or diabetes + additional risk factors; also adjunct to diet to reduce TG in severe hypertriglyceridemia.
In the REDUCE-IT clinical trial, patients taking Vascepa experienced a significant reduction in cardiovascular events compared with placebo.
14.1: VASCEPA significantly reduced the risk for the primary composite endpoint and key secondary composite endpoint vs placebo.
In the REDUCE-IT clinical trial, Vascepa reduced cardiovascular events including myocardial infarction and stroke compared with placebo.
14.1: key secondary composite endpoint includes cardiovascular death, myocardial infarction, or stroke; primary endpoint includes myocardial infarction and stroke.
There is a potential interaction between Vascepa and statins that could affect the risk of bleeding.
5.3 Bleeding: incidence of bleeding greater in patients receiving concomitant antithrombotic medications; and label context indicates statin-treated trial population (14.1). However, the excerpt does not directly frame a “statins” interaction for bleeding risk.
Unsupported Statements
Vascepa is often used in conjunction with statins to manage cholesterol levels.
1 INDICATIONS AND USAGE specifies VASCEPA as an adjunct to maximally tolerated statin therapy, but the excerpt does not state “often used” or that it is used “to manage cholesterol levels.”
Research suggests Vascepa is generally safe for long-term use.
The provided label excerpts do not state “generally safe” for long-term use; they describe trial duration (median 4.9 years) and adverse reactions/risks but do not make a general safety conclusion.
Vascepa and statins have antiplatelet effects that can increase the risk of bleeding.
5.3 Bleeding discusses increased bleeding and concomitant antithrombotic medications, but the provided excerpts do not describe statins or VASCEPA together as “antiplatelet effects.” 12.1 mentions EPA inhibits platelet aggregation in some ex vivo conditions, but the claim as phrased is not directly supported in the provided interaction/bleeding excerpt.
The combination of Vascepa and statins increased the risk of bleeding compared with either medication used alone.
5.3 Bleeding provides bleeding incidence vs placebo and notes increased incidence with concomitant antithrombotic medications; it does not compare combination vs either medication alone.
The bleeding risk from using Vascepa with statins is relatively low.
5.3 provides absolute event rates vs placebo but does not characterize bleeding risk with statins as “relatively low.”
The patent for Vascepa expired in 2025.
No patent/market exclusivity information is included in the provided label excerpts.
Contradictions
Low
AI Statement
The bleeding risk from using Vascepa with statins is relatively low.
Label Reference
5.3 Bleeding: VASCEPA is associated with an increased risk of bleeding and serious bleeding events occurred more often vs placebo; the label does not support a “relatively low” characterization.
Important Omissions
Dosage and administration details (e.g., 4 g/day dosing regimen, capsule swallowing instructions, and taking with food).
Importance:
Moderate
Key limitations of use and full indication criteria (e.g., requirement for elevated TG ≥150 mg/dL with established CVD or diabetes + additional risk factors for cardiovascular risk reduction; and TG ≥500 mg/dL for hypertriglyceridemia indication).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported/over-generalized statements about bleeding risk with statins and long-term safety could mislead risk perception. The patent-expiration claim is irrelevant to patient safety but indicates potential factual inaccuracies.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several claims are not supported by the provided label excerpts (e.g., “often used with statins to manage cholesterol,” “generally safe for long-term use,” and specific comparative bleeding conclusions/“relatively low” characterization), and one claim is unrelated to labeling (patent expiry).
Suggested Improvement
Limit statements to what the provided label excerpts support: specify the on-label adjunct-to-statin population/indication criteria, describe bleeding as increased vs placebo and monitor with concomitant antithrombotics as directed, avoid unlabelled characterizations (e.g., “relatively low” risk, general long-term safety), and omit non-label patent/expiration assertions.